The USFDA has approved anacaulase-bcdb, a botanical product containing proteolytic enzymes, to remove eschar in adult patients with deep partial- and/or full-thickness thermal burns. The approval was based on data obtained in pre-clinical and clinical trials, including a pivotal phase 3 clinical study (DETECT). Indication Eschar removal in adults with deep partial- and/or full-thickness thermal burns DETECT trial Administration Topical application by trained healthcare professionals in special burn centers The anacaulase-bcdb powder mixed with the gel is uniformly applied to a clean, blister-free, and moist wound area and covered with an occlusive film dressing for four hours Two applications of anacaulase-bcdb for four hours each are recommended.
A first application to an area of up to 15% body surface area, followed by a second application 24 hours later. Both applications must not…
